Colchicine for secondary prevention of vascular events: a meta-analysis of trials
Marc-André d’Entremont(Centre Hospitalier Universitaire de Sherbrooke), Sanjit S. Jolly(Population Health Research Institute), Jan H. Cornel(Brigham and Women's Hospital), Aernoud T.L. Fiolet(University Medical Center Utrecht), Michiel H.F. Poorthuis(University Medical Center Utrecht), Gilles Montalescot(Maastricht University Medical Centre), Ian Buysschaert(AZ Sint-Jan), Arend Mosterd(Werkgroep Cardiologische centra Nederland), Shirley Jansen(Harry Perkins Institute of Medical Research), Binita Shah(New York University), Martin Teraa(Maine Farmland Trust), Noel Chan(Chinese University of Hong Kong), Domingo A. Pascual‐Figal(Spanish National Centre for Cardiovascular Research), Jamie Layland(Peninsula Health), Peter J. Kelly(University College Dublin), Sasko Kedev(Ss. Cyril and Methodius University in Skopje), John W. Eikelboom(Population Health Research Institute), Kevin E. Boczar(University of Ottawa), Yongjun Wang(Shanghai University of Traditional Chinese Medicine), Pierre Amarenco(Population Health Research Institute), Alfredo E. Rodríguez, Jalina Jannink(Meander Medisch Centrum), Nathan Mewton(Hospices Civils de Lyon), Aimee van Zelm(University Medical Center Utrecht), Anthony Keech(Heidelberg University)
Cited by 43
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k
Autophagy regulates lipid metabolism
|Nature|2009|3.9k